Search

Your search keyword '"Pellicanò, Giovanni"' showing total 211 results

Search Constraints

Start Over You searched for: Author "Pellicanò, Giovanni" Remove constraint Author: "Pellicanò, Giovanni"
211 results on '"Pellicanò, Giovanni"'

Search Results

1. Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens

2. Incident diabetes in course of antiretroviral therapy

3. Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?

6. Risk of Cardiovascular Events in People with HIV (PWH) Treated with Integrase Strand-Transfer Inhibitors: The Debate Is Not Over; Results of the SCOLTA Study

7. Risk of Cardiovascular Events in People with HIV (PWH) Treated with Integrase Strand-Transfer Inhibitors: The Debate Is Not Over; Results of the SCOLTA Study

8. 1986. Switching to DOR/3TC/TDF Improves Renal Function and Decreases Lipid Levels in People Living With HIV: a Real-Life Multicentric Study

10. SARS-CoV-2 mRNA vaccination and short-term changes in viral load and CD4/CD8 T-cell counts in people living with HIV

11. Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting

12. SARS-CoV-2 mRNA Vaccine Response in People Living with HIV According to CD4 Count and CD4/CD8 Ratio.

13. Causes of HIV Treatment Interruption during the Last 20 Years: A Multi-Cohort Real-Life Study

14. Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting

15. Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir

16. Prevalence of HDV infection in people living with HIV: Data from a multicenter Italian cohort

17. Incident diabetes in course of antiretroviral therapy

18. Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens

19. Causes of HIV Treatment Interruption during the Last 20 Years: A Multi-Cohort Real-Life Study

20. Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA)

21. Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir.

22. Prevalence of HDV infection in people living with HIV: Data from a multicenter Italian cohort

24. When the eye does not see, the bone can grieve: An unusual presentation of secondary syphilis

25. Trajectories of CD4+/CD8+ T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study

26. Efficacy of COVID-19 Vaccination in People Living with HIV: A Public Health Fundamental Tool for the Protection of Patients and the Correct Management of Infection

29. ALIMENTAZIONE, AMBIENTE E SALUTE

30. The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile

31. Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?

32. Trajectories of CD4+/CD8+ T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study

33. Pulmonary Kaposi Sarcoma without Respiratory Symptoms and Skin Lesions in an HIV-Naïve Patient: A Case Report and Literature Review

34. Additional file 1 of Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?

36. Trajectories of CD4 + /CD8 + T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study.

37. Switch da Tenofovir disoproxil fumarato (TDF) a Tenofovir alafenamide (TAF) e aumento del colesterolo: impatto sulla valutazione del rischio cardiovascolare

38. Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepaICONA Foundation Cohort Study

40. Determinants of loss to care and risk of clinical progression in PLWH who are re-engaged in care after a temporary loss

41. Does Syphilis Increase the Risk of HIV-RNA Elevation >200 Copies/mL in HIV-Positive Patients Under Effective Antiretroviral Treatment? Data From the ICONA Cohort

42. Pre-cART inflammation, microbial translocation and Long-Term probability of clinical progressione in people living with HIV

43. Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study

44. Switch da Tenofovir disoproxil fumarato (TDF) a Tenofovir alafenamide (TAF) e aumento del colesterolo: impatto sulla valutazione del rischio cardiovascolare

45. Factors Associated With Weight Gain in People Treated With Dolutegravir

50. Factors Associated With Weight Gain in People Treated With Dolutegravir

Catalog

Books, media, physical & digital resources